
Paul LeVine, vice president of Analytic Services at TrialCard, discusses how specialty pharmacies can best support patients on a specialty drug therapy.

Paul LeVine, vice president of Analytic Services at TrialCard, discusses how specialty pharmacies can best support patients on a specialty drug therapy.

Sheila Arquette, RPh, director of Pharmacy Services for Independent Health, discusses developments in the specialty pharmacy landscape for stakeholders to monitor.

Mark A. Vineis, vice president of Specialty Pharmacy at Cardinal Health, discusses how the growing population of older Americans could impact the specialty pharmacy landscape.

Kevin James, RPh, MBA, vice president of Payer Strategy at US Bioservices, discusses lessons the specialty industry learned from the impact of high cost drug launches for hepatitis C and high cholesterol.

Erin Hohman, PharmD, BCPS, director of Clinical Pharmacy Services at Amber Pharmacy, discusses the relationship between limited distribution networks and specialty pharmacy.

Autumn Bagwell, PharmD, BCPS, clinical pharmacist at Vanderbilt Specialty Pharmacy, discusses how to address the challenge of access to high cost specialty medications.





















Mark Tesell, PharmD, BCPS, clinical consultant pharmacist for UMass Medical School Clinical Pharmacy Services, discusses potential solutions for access to cholesterol lowering drugs to improve.

Suzette DiMascio, CHE, CMCE, CPC, president and CEO of CSI Specialty Group, discusses how specialty pharmacies may need to alter current strategies with increasing attention on high drug costs.

Rebekah L. Hanson, PharmD, BCPS, BCACP, clinical pharmacist and assistant professor at the UIC College of Pharmacy, discusses the challenge of out-of-pocket spending and the impact on drug adherence.

Kevin James, RPh, MBA, vice president of payer strategy at US Bioservices, discusses challenges for patients in accessing specialty medications.